ProCE Banner Activity

ALTA-1L: Phase III Trial of Brigatinib vs Crizotinib in ALK Inhibitor–Naive Patients With ALK-Positive Advanced NSCLC

Slideset Download
Conference Coverage

In this first interim analysis, brigatinib showed significantly prolonged PFS vs crizotinib in the overall population and across most subgroups.

Released: September 27, 2018

Expiration: September 26, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants

AbbVie

AstraZeneca

Genentech TEXT Only

Takeda Oncology